26,27-homologated-20-epi-2-alkylidene-19-nor-vitamin D compounds

• US 7,094,774 B2
• Filed: 02/17/2004
• Issued: 08/22/2006
• Est. Priority Date: 03/17/1997
• Status: Expired due to Term

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: DeLuca, Hector F., Sicinski, Rafal R.
• Primary Examiner(s): QAZI, SABIHA NAIM
• Application Number:
  US10/780,103
• Publication Number:
  US 20040167104A1
• Time in Patent Office: 917 Days
• Field of Search: 552/653, 514/167
• US Class Current: 514/167
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 5/18 of the parathyroid hormones
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 : Antihypertensives
• CPC Class Codes: C07C 401/00 : Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
• CPC Class Codes: C07F 7/1804 : Compounds having Si-O-C linkages Si-O-acyl linkages C07F7/1896
• CPC Class Codes: Y02P 20/55 : Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

This invention provides a novel class of vitamin D related compounds, namely, the 2-alkylidene-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula:

where Y₁ and Y₂, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R₆ and R₈, which may be the same or different, are each selected from hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or when taken together represent the group —(CH₂)_x— where x is an integer from 2 to 5, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 2-substituted compounds are characterized by relatively high intestinal calcium transport activity and relatively high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.

Claims

1. A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-1α

,25-dihydroxy-2-methylene26,27-dihomo- 19-norvitainin D₃ having the structure

2. The method of claim 1 wherein the compound is administered orally.

3. The method of claim 1 wherein the compound is administered parenterally.

4. The method of claim 1 wherein the compound is administered transdermally.

5. The method of claim 1 wherein said effective amount comprises about 0.01 μ

g/day to about 100 μ

g/day of 20(S)-1α

,25-dihydroxy-2-methylene-26,27-dihomo- 19-norvitamin D₃.

6. The method of claim 1 wherein said effective amount comprises about 0.1 μ

g/day to about 50 μ

g/day of 20(S)-1α

,25-dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D₃.

7. A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃ having the structure

8. The method of claim 7 wherein the compound is administered orally.

9. The method of claim 7 wherein the compound is administered parenterally.

10. The method of claim 7 wherein the compound is administered transdermally.

11. The method of claim 7 wherein said effective amount comprises about 0.1 μ

g/day to about 100 μ

g/day of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃.

12. The method of claim 7 wherein said effective amount comprises about 0.1 μ

g/day to about 50 μ

g/day of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃.

13. A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S-1α

,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D₃ having the structure

14. The method of claim 13 wherein the compound is administered orally.

15. The method of claim 13 wherein the compound is administered parenterally.

16. The method of claim 13 wherein the compound is administered transdermally.

17. The method of claim 13 wherein said effective amount comprises about 0.01 μ

g/day to about 100 μ

g/day of 20(S)-1α

,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D₃.

18. The method of claim 13 wherein said effective amount comprises about 0.1 μ

g/day to about 50 μ

g/day of 20(S)-1α

,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D₃.

19. A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene-1α

-hydroxy-2-methylene-24-dehydro-19-norvitamin D₃ having the structure

20. The method of claim 19 wherein the compound is administered orally.

21. The method of claim 19 wherein the compound is administered parenterally.

22. The method of claim 19 wherein the compound is administered transdermally.

23. The method of claim 19 wherein said effective amount comprises about 0.01 μ

g/day to about 100 μ

g/day of 20(S)-26,27-dimethylene-1α

-hydroxy-2-methylene-24-dehydro-19-norvitamin D₃.

24. The method of claim 19 wherein said effective amount comprises about 0.1 μ

g/day to about 50 μ

g/day of20(S)-26,27-dimetyyl-1α

-hydroxy-2-methylene-24-dehydro-19-norvitamin D₃.